nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—L-DOPA—Melphalan—ovarian cancer	0.717	1	CrCrCtD
Methyldopa—DDC—embryo—ovarian cancer	0.00554	0.086	CbGeAlD
Methyldopa—DDC—Dopaminergic Neurogenesis—LMX1A—ovarian cancer	0.00473	0.209	CbGpPWpGaD
Methyldopa—COMT—myometrium—ovarian cancer	0.00381	0.0591	CbGeAlD
Methyldopa—SLC15A1—epithelium—ovarian cancer	0.00336	0.0522	CbGeAlD
Methyldopa—DDC—female reproductive system—ovarian cancer	0.00336	0.0521	CbGeAlD
Methyldopa—SLC15A1—endometrium—ovarian cancer	0.00301	0.0468	CbGeAlD
Methyldopa—COMT—uterine cervix—ovarian cancer	0.00296	0.046	CbGeAlD
Methyldopa—COMT—decidua—ovarian cancer	0.00282	0.0438	CbGeAlD
Methyldopa—DDC—testis—ovarian cancer	0.00271	0.0421	CbGeAlD
Methyldopa—Isoprenaline—MAPK1—ovarian cancer	0.00269	1	CrCbGaD
Methyldopa—COMT—endometrium—ovarian cancer	0.00268	0.0416	CbGeAlD
Methyldopa—COMT—gonad—ovarian cancer	0.00249	0.0386	CbGeAlD
Methyldopa—COMT—uterus—ovarian cancer	0.00247	0.0384	CbGeAlD
Methyldopa—SLC15A1—vagina—ovarian cancer	0.00226	0.0351	CbGeAlD
Methyldopa—COMT—female reproductive system—ovarian cancer	0.00222	0.0345	CbGeAlD
Methyldopa—COMT—bone marrow—ovarian cancer	0.0021	0.0326	CbGeAlD
Methyldopa—COMT—female gonad—ovarian cancer	0.00202	0.0314	CbGeAlD
Methyldopa—COMT—vagina—ovarian cancer	0.00201	0.0312	CbGeAlD
Methyldopa—DDC—lymph node—ovarian cancer	0.00196	0.0305	CbGeAlD
Methyldopa—ADRA2A—myometrium—ovarian cancer	0.00194	0.0301	CbGeAlD
Methyldopa—COMT—testis—ovarian cancer	0.00179	0.0278	CbGeAlD
Methyldopa—DDC—Amine-derived hormones—SLC5A5—ovarian cancer	0.00164	0.0727	CbGpPWpGaD
Methyldopa—DDC—Dopamine metabolism—SOD1—ovarian cancer	0.0016	0.0709	CbGpPWpGaD
Methyldopa—ADRA2A—uterine cervix—ovarian cancer	0.00151	0.0234	CbGeAlD
Methyldopa—ADRA2A—decidua—ovarian cancer	0.00144	0.0223	CbGeAlD
Methyldopa—COMT—Dopamine metabolism—SOD1—ovarian cancer	0.00142	0.0629	CbGpPWpGaD
Methyldopa—ADRA2A—endometrium—ovarian cancer	0.00137	0.0212	CbGeAlD
Methyldopa—COMT—lymph node—ovarian cancer	0.0013	0.0202	CbGeAlD
Methyldopa—ADRA2A—gonad—ovarian cancer	0.00127	0.0197	CbGeAlD
Methyldopa—ADRA2A—uterus—ovarian cancer	0.00126	0.0195	CbGeAlD
Methyldopa—COMT—Estrogen metabolism—CYP1B1—ovarian cancer	0.00123	0.0544	CbGpPWpGaD
Methyldopa—ADRA2A—female reproductive system—ovarian cancer	0.00113	0.0176	CbGeAlD
Methyldopa—DDC—Parkinsons Disease Pathway—PARK2—ovarian cancer	0.00109	0.0482	CbGpPWpGaD
Methyldopa—ADRA2A—female gonad—ovarian cancer	0.00103	0.016	CbGeAlD
Methyldopa—ADRA2A—vagina—ovarian cancer	0.00102	0.0159	CbGeAlD
Methyldopa—ADRA2A—testis—ovarian cancer	0.000913	0.0142	CbGeAlD
Methyldopa—Orthostatic hypotension—Paclitaxel—ovarian cancer	0.000707	0.00365	CcSEcCtD
Methyldopa—Breast disorder—Paclitaxel—ovarian cancer	0.000699	0.00361	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Paclitaxel—ovarian cancer	0.000697	0.0036	CcSEcCtD
Methyldopa—Amenorrhoea—Epirubicin—ovarian cancer	0.000694	0.00358	CcSEcCtD
Methyldopa—Arthralgia—Topotecan—ovarian cancer	0.00069	0.00356	CcSEcCtD
Methyldopa—Myalgia—Topotecan—ovarian cancer	0.00069	0.00356	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.000685	0.00354	CcSEcCtD
Methyldopa—Myalgia—Melphalan—ovarian cancer	0.000675	0.00349	CcSEcCtD
Methyldopa—Abdominal distension—Paclitaxel—ovarian cancer	0.000673	0.00348	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.000671	0.00346	CcSEcCtD
Methyldopa—Liver injury—Doxorubicin—ovarian cancer	0.00067	0.00346	CcSEcCtD
Methyldopa—ADRA2A—lymph node—ovarian cancer	0.000662	0.0103	CbGeAlD
Methyldopa—Infection—Topotecan—ovarian cancer	0.000657	0.00339	CcSEcCtD
Methyldopa—Pancreatitis—Paclitaxel—ovarian cancer	0.000656	0.00339	CcSEcCtD
Methyldopa—DDC—Tryptophan metabolism—CYP1B1—ovarian cancer	0.000654	0.0289	CbGpPWpGaD
Methyldopa—Nervous system disorder—Topotecan—ovarian cancer	0.000648	0.00335	CcSEcCtD
Methyldopa—Oedema—Melphalan—ovarian cancer	0.000647	0.00334	CcSEcCtD
Methyldopa—Thrombocytopenia—Topotecan—ovarian cancer	0.000647	0.00334	CcSEcCtD
Methyldopa—Infection—Melphalan—ovarian cancer	0.000643	0.00332	CcSEcCtD
Methyldopa—Skin disorder—Topotecan—ovarian cancer	0.000642	0.00332	CcSEcCtD
Methyldopa—Amenorrhoea—Doxorubicin—ovarian cancer	0.000642	0.00332	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.000641	0.00331	CcSEcCtD
Methyldopa—Pancytopenia—Paclitaxel—ovarian cancer	0.000635	0.00328	CcSEcCtD
Methyldopa—Thrombocytopenia—Melphalan—ovarian cancer	0.000634	0.00327	CcSEcCtD
Methyldopa—Skin disorder—Melphalan—ovarian cancer	0.000629	0.00325	CcSEcCtD
Methyldopa—DDC—Parkinsons Disease Pathway—CCNE1—ovarian cancer	0.000627	0.0278	CbGpPWpGaD
Methyldopa—Leukopenia—Vinorelbine—ovarian cancer	0.00062	0.0032	CcSEcCtD
Methyldopa—Hepatocellular injury—Epirubicin—ovarian cancer	0.000609	0.00315	CcSEcCtD
Methyldopa—Weight increased—Paclitaxel—ovarian cancer	0.000609	0.00314	CcSEcCtD
Methyldopa—Liver function test abnormal—Docetaxel—ovarian cancer	0.000606	0.00313	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.000602	0.00311	CcSEcCtD
Methyldopa—Orthostatic hypotension—Docetaxel—ovarian cancer	0.000599	0.00309	CcSEcCtD
Methyldopa—Infestation—Paclitaxel—ovarian cancer	0.000596	0.00308	CcSEcCtD
Methyldopa—Infestation NOS—Paclitaxel—ovarian cancer	0.000596	0.00308	CcSEcCtD
Methyldopa—Paraesthesia—Topotecan—ovarian cancer	0.000594	0.00307	CcSEcCtD
Methyldopa—Breast disorder—Docetaxel—ovarian cancer	0.000593	0.00306	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Docetaxel—ovarian cancer	0.000591	0.00305	CcSEcCtD
Methyldopa—Myalgia—Vinorelbine—ovarian cancer	0.00059	0.00305	CcSEcCtD
Methyldopa—Arthralgia—Vinorelbine—ovarian cancer	0.00059	0.00305	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.00059	0.00305	CcSEcCtD
Methyldopa—Body temperature increased—Chlorambucil—ovarian cancer	0.000587	0.00303	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000586	0.00303	CcSEcCtD
Methyldopa—Colitis—Epirubicin—ovarian cancer	0.000585	0.00302	CcSEcCtD
Methyldopa—Paraesthesia—Melphalan—ovarian cancer	0.000581	0.003	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000571	0.00295	CcSEcCtD
Methyldopa—Constipation—Topotecan—ovarian cancer	0.000565	0.00292	CcSEcCtD
Methyldopa—Hepatobiliary disease—Paclitaxel—ovarian cancer	0.000564	0.00291	CcSEcCtD
Methyldopa—Hepatocellular injury—Doxorubicin—ovarian cancer	0.000564	0.00291	CcSEcCtD
Methyldopa—Infection—Vinorelbine—ovarian cancer	0.000562	0.0029	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000559	0.00289	CcSEcCtD
Methyldopa—Nervous system disorder—Vinorelbine—ovarian cancer	0.000555	0.00286	CcSEcCtD
Methyldopa—Thrombocytopenia—Vinorelbine—ovarian cancer	0.000554	0.00286	CcSEcCtD
Methyldopa—Angina pectoris—Docetaxel—ovarian cancer	0.000552	0.00285	CcSEcCtD
Methyldopa—Skin disorder—Vinorelbine—ovarian cancer	0.000549	0.00284	CcSEcCtD
Methyldopa—Hypersensitivity—Chlorambucil—ovarian cancer	0.000547	0.00283	CcSEcCtD
Methyldopa—Bradycardia—Paclitaxel—ovarian cancer	0.000545	0.00282	CcSEcCtD
Methyldopa—Colitis—Doxorubicin—ovarian cancer	0.000541	0.0028	CcSEcCtD
Methyldopa—Pancytopenia—Docetaxel—ovarian cancer	0.000538	0.00278	CcSEcCtD
Methyldopa—Asthenia—Chlorambucil—ovarian cancer	0.000533	0.00275	CcSEcCtD
Methyldopa—Connective tissue disorder—Paclitaxel—ovarian cancer	0.000526	0.00272	CcSEcCtD
Methyldopa—Body temperature increased—Topotecan—ovarian cancer	0.000523	0.0027	CcSEcCtD
Methyldopa—Weight increased—Docetaxel—ovarian cancer	0.000516	0.00267	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.000515	0.00266	CcSEcCtD
Methyldopa—Diarrhoea—Chlorambucil—ovarian cancer	0.000508	0.00262	CcSEcCtD
Methyldopa—Paraesthesia—Vinorelbine—ovarian cancer	0.000508	0.00262	CcSEcCtD
Methyldopa—Infestation—Docetaxel—ovarian cancer	0.000505	0.00261	CcSEcCtD
Methyldopa—Infestation NOS—Docetaxel—ovarian cancer	0.000505	0.00261	CcSEcCtD
Methyldopa—Cardiac disorder—Paclitaxel—ovarian cancer	0.000497	0.00257	CcSEcCtD
Methyldopa—Jaundice—Docetaxel—ovarian cancer	0.000493	0.00255	CcSEcCtD
Methyldopa—Eczema—Epirubicin—ovarian cancer	0.000492	0.00254	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000488	0.00252	CcSEcCtD
Methyldopa—Cardiac failure congestive—Epirubicin—ovarian cancer	0.000488	0.00252	CcSEcCtD
Methyldopa—Hypersensitivity—Topotecan—ovarian cancer	0.000487	0.00252	CcSEcCtD
Methyldopa—Angiopathy—Paclitaxel—ovarian cancer	0.000486	0.00251	CcSEcCtD
Methyldopa—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC5A5—ovarian cancer	0.000484	0.0214	CbGpPWpGaD
Methyldopa—Constipation—Vinorelbine—ovarian cancer	0.000484	0.0025	CcSEcCtD
Methyldopa—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000482	0.00249	CcSEcCtD
Methyldopa—Hepatobiliary disease—Docetaxel—ovarian cancer	0.000478	0.00247	CcSEcCtD
Methyldopa—Hypersensitivity—Melphalan—ovarian cancer	0.000477	0.00246	CcSEcCtD
Methyldopa—Asthenia—Topotecan—ovarian cancer	0.000474	0.00245	CcSEcCtD
Methyldopa—Vomiting—Chlorambucil—ovarian cancer	0.000472	0.00244	CcSEcCtD
Methyldopa—Agranulocytosis—Docetaxel—ovarian cancer	0.000472	0.00244	CcSEcCtD
Methyldopa—Mental disorder—Paclitaxel—ovarian cancer	0.000469	0.00242	CcSEcCtD
Methyldopa—Asthenia—Melphalan—ovarian cancer	0.000464	0.0024	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—TOP1—ovarian cancer	0.000462	0.0204	CbGpPWpGaD
Methyldopa—Flatulence—Paclitaxel—ovarian cancer	0.000459	0.00237	CcSEcCtD
Methyldopa—Eczema—Doxorubicin—ovarian cancer	0.000455	0.00235	CcSEcCtD
Methyldopa—Hepatitis—Docetaxel—ovarian cancer	0.000454	0.00234	CcSEcCtD
Methyldopa—Diarrhoea—Topotecan—ovarian cancer	0.000452	0.00234	CcSEcCtD
Methyldopa—Cardiac failure congestive—Doxorubicin—ovarian cancer	0.000451	0.00233	CcSEcCtD
Methyldopa—Body temperature increased—Vinorelbine—ovarian cancer	0.000447	0.00231	CcSEcCtD
Methyldopa—Connective tissue disorder—Docetaxel—ovarian cancer	0.000446	0.0023	CcSEcCtD
Methyldopa—Diarrhoea—Melphalan—ovarian cancer	0.000443	0.00229	CcSEcCtD
Methyldopa—Nausea—Chlorambucil—ovarian cancer	0.000441	0.00228	CcSEcCtD
Methyldopa—Dizziness—Topotecan—ovarian cancer	0.000437	0.00226	CcSEcCtD
Methyldopa—COMT—Transmission across Chemical Synapses—NSF—ovarian cancer	0.000423	0.0187	CbGpPWpGaD
Methyldopa—Cardiac disorder—Docetaxel—ovarian cancer	0.000421	0.00218	CcSEcCtD
Methyldopa—Vomiting—Topotecan—ovarian cancer	0.00042	0.00217	CcSEcCtD
Methyldopa—Leukopenia—Paclitaxel—ovarian cancer	0.000417	0.00215	CcSEcCtD
Methyldopa—Rash—Topotecan—ovarian cancer	0.000417	0.00215	CcSEcCtD
Methyldopa—Hypersensitivity—Vinorelbine—ovarian cancer	0.000417	0.00215	CcSEcCtD
Methyldopa—Dermatitis—Topotecan—ovarian cancer	0.000416	0.00215	CcSEcCtD
Methyldopa—Headache—Topotecan—ovarian cancer	0.000414	0.00214	CcSEcCtD
Methyldopa—Angiopathy—Docetaxel—ovarian cancer	0.000412	0.00213	CcSEcCtD
Methyldopa—Vomiting—Melphalan—ovarian cancer	0.000412	0.00213	CcSEcCtD
Methyldopa—Mediastinal disorder—Docetaxel—ovarian cancer	0.000409	0.00211	CcSEcCtD
Methyldopa—Liver function test abnormal—Epirubicin—ovarian cancer	0.000408	0.00211	CcSEcCtD
Methyldopa—Rash—Melphalan—ovarian cancer	0.000408	0.00211	CcSEcCtD
Methyldopa—Dermatitis—Melphalan—ovarian cancer	0.000408	0.00211	CcSEcCtD
Methyldopa—Asthenia—Vinorelbine—ovarian cancer	0.000406	0.0021	CcSEcCtD
Methyldopa—Orthostatic hypotension—Epirubicin—ovarian cancer	0.000404	0.00209	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—PPP1CC—ovarian cancer	0.000403	0.0179	CbGpPWpGaD
Methyldopa—Breast disorder—Epirubicin—ovarian cancer	0.0004	0.00207	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.000398	0.00206	CcSEcCtD
Methyldopa—Mental disorder—Docetaxel—ovarian cancer	0.000398	0.00205	CcSEcCtD
Methyldopa—Myalgia—Paclitaxel—ovarian cancer	0.000397	0.00205	CcSEcCtD
Methyldopa—Arthralgia—Paclitaxel—ovarian cancer	0.000397	0.00205	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000394	0.00204	CcSEcCtD
Methyldopa—Nausea—Topotecan—ovarian cancer	0.000393	0.00203	CcSEcCtD
Methyldopa—Diarrhoea—Vinorelbine—ovarian cancer	0.000387	0.002	CcSEcCtD
Methyldopa—Abdominal distension—Epirubicin—ovarian cancer	0.000385	0.00199	CcSEcCtD
Methyldopa—Nausea—Melphalan—ovarian cancer	0.000384	0.00199	CcSEcCtD
Methyldopa—Oedema—Paclitaxel—ovarian cancer	0.00038	0.00196	CcSEcCtD
Methyldopa—Eosinophilia—Epirubicin—ovarian cancer	0.000379	0.00196	CcSEcCtD
Methyldopa—Liver function test abnormal—Doxorubicin—ovarian cancer	0.000378	0.00195	CcSEcCtD
Methyldopa—Infection—Paclitaxel—ovarian cancer	0.000378	0.00195	CcSEcCtD
Methyldopa—Pancreatitis—Epirubicin—ovarian cancer	0.000375	0.00194	CcSEcCtD
Methyldopa—Dizziness—Vinorelbine—ovarian cancer	0.000374	0.00193	CcSEcCtD
Methyldopa—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.000374	0.00193	CcSEcCtD
Methyldopa—Nervous system disorder—Paclitaxel—ovarian cancer	0.000373	0.00193	CcSEcCtD
Methyldopa—Angina pectoris—Epirubicin—ovarian cancer	0.000372	0.00192	CcSEcCtD
Methyldopa—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000372	0.00192	CcSEcCtD
Methyldopa—Breast disorder—Doxorubicin—ovarian cancer	0.00037	0.00191	CcSEcCtD
Methyldopa—Skin disorder—Paclitaxel—ovarian cancer	0.000369	0.00191	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.000369	0.0019	CcSEcCtD
Methyldopa—Pancytopenia—Epirubicin—ovarian cancer	0.000363	0.00188	CcSEcCtD
Methyldopa—Vomiting—Vinorelbine—ovarian cancer	0.00036	0.00186	CcSEcCtD
Methyldopa—Rash—Vinorelbine—ovarian cancer	0.000357	0.00184	CcSEcCtD
Methyldopa—Dermatitis—Vinorelbine—ovarian cancer	0.000356	0.00184	CcSEcCtD
Methyldopa—Abdominal distension—Doxorubicin—ovarian cancer	0.000356	0.00184	CcSEcCtD
Methyldopa—Headache—Vinorelbine—ovarian cancer	0.000354	0.00183	CcSEcCtD
Methyldopa—Leukopenia—Docetaxel—ovarian cancer	0.000354	0.00183	CcSEcCtD
Methyldopa—Eosinophilia—Doxorubicin—ovarian cancer	0.00035	0.00181	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—HNF1B—ovarian cancer	0.00035	0.0155	CbGpPWpGaD
Methyldopa—Weight increased—Epirubicin—ovarian cancer	0.000348	0.0018	CcSEcCtD
Methyldopa—Pancreatitis—Doxorubicin—ovarian cancer	0.000347	0.00179	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000347	0.00179	CcSEcCtD
Methyldopa—Angina pectoris—Doxorubicin—ovarian cancer	0.000345	0.00178	CcSEcCtD
Methyldopa—Paraesthesia—Paclitaxel—ovarian cancer	0.000342	0.00176	CcSEcCtD
Methyldopa—Infestation NOS—Epirubicin—ovarian cancer	0.000341	0.00176	CcSEcCtD
Methyldopa—Infestation—Epirubicin—ovarian cancer	0.000341	0.00176	CcSEcCtD
Methyldopa—Arthralgia—Docetaxel—ovarian cancer	0.000336	0.00174	CcSEcCtD
Methyldopa—Myalgia—Docetaxel—ovarian cancer	0.000336	0.00174	CcSEcCtD
Methyldopa—Pancytopenia—Doxorubicin—ovarian cancer	0.000336	0.00174	CcSEcCtD
Methyldopa—Nausea—Vinorelbine—ovarian cancer	0.000336	0.00174	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000334	0.00173	CcSEcCtD
Methyldopa—Jaundice—Epirubicin—ovarian cancer	0.000332	0.00172	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000328	0.0017	CcSEcCtD
Methyldopa—Constipation—Paclitaxel—ovarian cancer	0.000325	0.00168	CcSEcCtD
Methyldopa—COMT—Neuronal System—NSF—ovarian cancer	0.000324	0.0143	CbGpPWpGaD
Methyldopa—DDC—Dopaminergic Neurogenesis—STAT3—ovarian cancer	0.000323	0.0143	CbGpPWpGaD
Methyldopa—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000322	0.00167	CcSEcCtD
Methyldopa—Oedema—Docetaxel—ovarian cancer	0.000322	0.00167	CcSEcCtD
Methyldopa—Weight increased—Doxorubicin—ovarian cancer	0.000322	0.00166	CcSEcCtD
Methyldopa—Infection—Docetaxel—ovarian cancer	0.00032	0.00165	CcSEcCtD
Methyldopa—DDC—Parkinsons Disease Pathway—CASP3—ovarian cancer	0.000319	0.0141	CbGpPWpGaD
Methyldopa—Agranulocytosis—Epirubicin—ovarian cancer	0.000318	0.00164	CcSEcCtD
Methyldopa—Nervous system disorder—Docetaxel—ovarian cancer	0.000316	0.00163	CcSEcCtD
Methyldopa—Thrombocytopenia—Docetaxel—ovarian cancer	0.000316	0.00163	CcSEcCtD
Methyldopa—Infestation—Doxorubicin—ovarian cancer	0.000315	0.00163	CcSEcCtD
Methyldopa—Infestation NOS—Doxorubicin—ovarian cancer	0.000315	0.00163	CcSEcCtD
Methyldopa—Skin disorder—Docetaxel—ovarian cancer	0.000313	0.00162	CcSEcCtD
Methyldopa—Bradycardia—Epirubicin—ovarian cancer	0.000312	0.00161	CcSEcCtD
Methyldopa—Jaundice—Doxorubicin—ovarian cancer	0.000307	0.00159	CcSEcCtD
Methyldopa—Hepatitis—Epirubicin—ovarian cancer	0.000306	0.00158	CcSEcCtD
Methyldopa—Connective tissue disorder—Epirubicin—ovarian cancer	0.000301	0.00155	CcSEcCtD
Methyldopa—Body temperature increased—Paclitaxel—ovarian cancer	0.000301	0.00155	CcSEcCtD
Methyldopa—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000298	0.00154	CcSEcCtD
Methyldopa—Agranulocytosis—Doxorubicin—ovarian cancer	0.000294	0.00152	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000294	0.00152	CcSEcCtD
Methyldopa—Paraesthesia—Docetaxel—ovarian cancer	0.000289	0.0015	CcSEcCtD
Methyldopa—Bradycardia—Doxorubicin—ovarian cancer	0.000288	0.00149	CcSEcCtD
Methyldopa—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—ovarian cancer	0.000285	0.0126	CbGpPWpGaD
Methyldopa—Cardiac disorder—Epirubicin—ovarian cancer	0.000284	0.00147	CcSEcCtD
Methyldopa—Hepatitis—Doxorubicin—ovarian cancer	0.000283	0.00146	CcSEcCtD
Methyldopa—Hypersensitivity—Paclitaxel—ovarian cancer	0.00028	0.00145	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000278	0.00144	CcSEcCtD
Methyldopa—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000278	0.00144	CcSEcCtD
Methyldopa—Angiopathy—Epirubicin—ovarian cancer	0.000278	0.00143	CcSEcCtD
Methyldopa—Mediastinal disorder—Epirubicin—ovarian cancer	0.000276	0.00142	CcSEcCtD
Methyldopa—Constipation—Docetaxel—ovarian cancer	0.000276	0.00142	CcSEcCtD
Methyldopa—Asthenia—Paclitaxel—ovarian cancer	0.000273	0.00141	CcSEcCtD
Methyldopa—Mental disorder—Epirubicin—ovarian cancer	0.000268	0.00139	CcSEcCtD
Methyldopa—Cardiac disorder—Doxorubicin—ovarian cancer	0.000263	0.00136	CcSEcCtD
Methyldopa—Flatulence—Epirubicin—ovarian cancer	0.000263	0.00136	CcSEcCtD
Methyldopa—Diarrhoea—Paclitaxel—ovarian cancer	0.00026	0.00134	CcSEcCtD
Methyldopa—Angiopathy—Doxorubicin—ovarian cancer	0.000257	0.00133	CcSEcCtD
Methyldopa—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000255	0.00132	CcSEcCtD
Methyldopa—Body temperature increased—Docetaxel—ovarian cancer	0.000255	0.00132	CcSEcCtD
Methyldopa—Dizziness—Paclitaxel—ovarian cancer	0.000252	0.0013	CcSEcCtD
Methyldopa—Mental disorder—Doxorubicin—ovarian cancer	0.000248	0.00128	CcSEcCtD
Methyldopa—Flatulence—Doxorubicin—ovarian cancer	0.000243	0.00125	CcSEcCtD
Methyldopa—Vomiting—Paclitaxel—ovarian cancer	0.000242	0.00125	CcSEcCtD
Methyldopa—Rash—Paclitaxel—ovarian cancer	0.00024	0.00124	CcSEcCtD
Methyldopa—Dermatitis—Paclitaxel—ovarian cancer	0.00024	0.00124	CcSEcCtD
Methyldopa—Leukopenia—Epirubicin—ovarian cancer	0.000238	0.00123	CcSEcCtD
Methyldopa—Headache—Paclitaxel—ovarian cancer	0.000238	0.00123	CcSEcCtD
Methyldopa—Hypersensitivity—Docetaxel—ovarian cancer	0.000238	0.00123	CcSEcCtD
Methyldopa—Asthenia—Docetaxel—ovarian cancer	0.000231	0.00119	CcSEcCtD
Methyldopa—DDC—Amino acid and derivative metabolism—SLC5A5—ovarian cancer	0.000229	0.0101	CbGpPWpGaD
Methyldopa—Myalgia—Epirubicin—ovarian cancer	0.000227	0.00117	CcSEcCtD
Methyldopa—Arthralgia—Epirubicin—ovarian cancer	0.000227	0.00117	CcSEcCtD
Methyldopa—Nausea—Paclitaxel—ovarian cancer	0.000226	0.00117	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000225	0.00116	CcSEcCtD
Methyldopa—Leukopenia—Doxorubicin—ovarian cancer	0.000221	0.00114	CcSEcCtD
Methyldopa—Diarrhoea—Docetaxel—ovarian cancer	0.000221	0.00114	CcSEcCtD
Methyldopa—Oedema—Epirubicin—ovarian cancer	0.000217	0.00112	CcSEcCtD
Methyldopa—Infection—Epirubicin—ovarian cancer	0.000216	0.00112	CcSEcCtD
Methyldopa—Nervous system disorder—Epirubicin—ovarian cancer	0.000213	0.0011	CcSEcCtD
Methyldopa—Dizziness—Docetaxel—ovarian cancer	0.000213	0.0011	CcSEcCtD
Methyldopa—Thrombocytopenia—Epirubicin—ovarian cancer	0.000213	0.0011	CcSEcCtD
Methyldopa—Skin disorder—Epirubicin—ovarian cancer	0.000211	0.00109	CcSEcCtD
Methyldopa—Arthralgia—Doxorubicin—ovarian cancer	0.00021	0.00108	CcSEcCtD
Methyldopa—Myalgia—Doxorubicin—ovarian cancer	0.00021	0.00108	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000208	0.00108	CcSEcCtD
Methyldopa—Vomiting—Docetaxel—ovarian cancer	0.000205	0.00106	CcSEcCtD
Methyldopa—Rash—Docetaxel—ovarian cancer	0.000203	0.00105	CcSEcCtD
Methyldopa—Dermatitis—Docetaxel—ovarian cancer	0.000203	0.00105	CcSEcCtD
Methyldopa—COMT—Biological oxidations—CYP1B1—ovarian cancer	0.000202	0.00894	CbGpPWpGaD
Methyldopa—Headache—Docetaxel—ovarian cancer	0.000202	0.00104	CcSEcCtD
Methyldopa—Oedema—Doxorubicin—ovarian cancer	0.000201	0.00104	CcSEcCtD
Methyldopa—Infection—Doxorubicin—ovarian cancer	0.0002	0.00103	CcSEcCtD
Methyldopa—COMT—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000199	0.00882	CbGpPWpGaD
Methyldopa—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000198	0.00102	CcSEcCtD
Methyldopa—Nervous system disorder—Doxorubicin—ovarian cancer	0.000197	0.00102	CcSEcCtD
Methyldopa—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000197	0.00102	CcSEcCtD
Methyldopa—Skin disorder—Doxorubicin—ovarian cancer	0.000195	0.00101	CcSEcCtD
Methyldopa—Paraesthesia—Epirubicin—ovarian cancer	0.000195	0.00101	CcSEcCtD
Methyldopa—Nausea—Docetaxel—ovarian cancer	0.000191	0.000989	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000188	0.00097	CcSEcCtD
Methyldopa—Constipation—Epirubicin—ovarian cancer	0.000186	0.000961	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000183	0.000947	CcSEcCtD
Methyldopa—Paraesthesia—Doxorubicin—ovarian cancer	0.000181	0.000933	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000174	0.000897	CcSEcCtD
Methyldopa—Constipation—Doxorubicin—ovarian cancer	0.000172	0.000889	CcSEcCtD
Methyldopa—Body temperature increased—Epirubicin—ovarian cancer	0.000172	0.000888	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—TYMS—ovarian cancer	0.000162	0.00719	CbGpPWpGaD
Methyldopa—Hypersensitivity—Epirubicin—ovarian cancer	0.00016	0.000828	CcSEcCtD
Methyldopa—ADRA2A—Regulation of insulin secretion—SLC2A1—ovarian cancer	0.000159	0.00705	CbGpPWpGaD
Methyldopa—Body temperature increased—Doxorubicin—ovarian cancer	0.000159	0.000822	CcSEcCtD
Methyldopa—Asthenia—Epirubicin—ovarian cancer	0.000156	0.000806	CcSEcCtD
Methyldopa—Diarrhoea—Epirubicin—ovarian cancer	0.000149	0.000769	CcSEcCtD
Methyldopa—Hypersensitivity—Doxorubicin—ovarian cancer	0.000148	0.000766	CcSEcCtD
Methyldopa—Asthenia—Doxorubicin—ovarian cancer	0.000144	0.000746	CcSEcCtD
Methyldopa—Dizziness—Epirubicin—ovarian cancer	0.000144	0.000743	CcSEcCtD
Methyldopa—DDC—Metabolism—NME2—ovarian cancer	0.000139	0.00614	CbGpPWpGaD
Methyldopa—Vomiting—Epirubicin—ovarian cancer	0.000138	0.000714	CcSEcCtD
Methyldopa—Diarrhoea—Doxorubicin—ovarian cancer	0.000138	0.000711	CcSEcCtD
Methyldopa—Rash—Epirubicin—ovarian cancer	0.000137	0.000708	CcSEcCtD
Methyldopa—Dermatitis—Epirubicin—ovarian cancer	0.000137	0.000708	CcSEcCtD
Methyldopa—Headache—Epirubicin—ovarian cancer	0.000136	0.000704	CcSEcCtD
Methyldopa—Dizziness—Doxorubicin—ovarian cancer	0.000133	0.000687	CcSEcCtD
Methyldopa—ADRA2A—Integration of energy metabolism—FASN—ovarian cancer	0.000132	0.00584	CbGpPWpGaD
Methyldopa—Nausea—Epirubicin—ovarian cancer	0.000129	0.000667	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—AQP3—ovarian cancer	0.000128	0.00567	CbGpPWpGaD
Methyldopa—Vomiting—Doxorubicin—ovarian cancer	0.000128	0.000661	CcSEcCtD
Methyldopa—SLC15A1—SLC-mediated transmembrane transport—SLC5A5—ovarian cancer	0.000127	0.00564	CbGpPWpGaD
Methyldopa—Rash—Doxorubicin—ovarian cancer	0.000127	0.000655	CcSEcCtD
Methyldopa—Dermatitis—Doxorubicin—ovarian cancer	0.000127	0.000655	CcSEcCtD
Methyldopa—Headache—Doxorubicin—ovarian cancer	0.000126	0.000651	CcSEcCtD
Methyldopa—ADRA2A—Integration of energy metabolism—SLC2A1—ovarian cancer	0.000125	0.00554	CbGpPWpGaD
Methyldopa—COMT—Metabolism—NME2—ovarian cancer	0.000123	0.00545	CbGpPWpGaD
Methyldopa—SLC15A1—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	0.000123	0.00545	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ATP7B—ovarian cancer	0.000123	0.00544	CbGpPWpGaD
Methyldopa—Nausea—Doxorubicin—ovarian cancer	0.00012	0.000617	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	0.000108	0.00476	CbGpPWpGaD
Methyldopa—ADRA2A—Integration of energy metabolism—PPP2R1A—ovarian cancer	0.000107	0.00471	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—CASP3—ovarian cancer	0.000103	0.00456	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	9.92e-05	0.00439	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	9.71e-05	0.0043	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CYTB—ovarian cancer	8.94e-05	0.00396	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	8.74e-05	0.00387	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—SPARC—ovarian cancer	8.06e-05	0.00357	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CYTB—ovarian cancer	7.94e-05	0.00351	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—PTEN—ovarian cancer	7.9e-05	0.0035	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PPP1CC—ovarian cancer	7.82e-05	0.00346	CbGpPWpGaD
Methyldopa—DDC—Metabolism—BRIP1—ovarian cancer	7.82e-05	0.00346	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—RAD51C—ovarian cancer	7.78e-05	0.00344	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PPP1CC—ovarian cancer	6.94e-05	0.00307	CbGpPWpGaD
Methyldopa—COMT—Metabolism—BRIP1—ovarian cancer	6.94e-05	0.00307	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	6.48e-05	0.00287	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	6.26e-05	0.00277	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet Aggregation (Plug Formation)—AKT1—ovarian cancer	6.22e-05	0.00275	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—IL6—ovarian cancer	6.04e-05	0.00267	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—SOD1—ovarian cancer	5.86e-05	0.00259	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—MAPK1—ovarian cancer	5.72e-05	0.00253	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—TP53—ovarian cancer	5.39e-05	0.00239	CbGpPWpGaD
Methyldopa—DDC—Metabolism—YAP1—ovarian cancer	5.24e-05	0.00232	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ABCB1—ovarian cancer	4.94e-05	0.00219	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—IL6—ovarian cancer	4.93e-05	0.00218	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NME2—ovarian cancer	4.9e-05	0.00217	CbGpPWpGaD
Methyldopa—COMT—Metabolism—YAP1—ovarian cancer	4.65e-05	0.00206	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—HRAS—ovarian cancer	4.59e-05	0.00203	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HSD17B6—ovarian cancer	4.48e-05	0.00198	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—MAPK1—ovarian cancer	4.39e-05	0.00194	CbGpPWpGaD
Methyldopa—DDC—Metabolism—FASN—ovarian cancer	4.27e-05	0.00189	CbGpPWpGaD
Methyldopa—DDC—Metabolism—SLC5A5—ovarian cancer	4.2e-05	0.00186	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SPARC—ovarian cancer	4.16e-05	0.00184	CbGpPWpGaD
Methyldopa—DDC—Metabolism—SLC2A1—ovarian cancer	4.06e-05	0.0018	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CG—ovarian cancer	3.9e-05	0.00173	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CYP1B1—ovarian cancer	3.89e-05	0.00172	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DLC1—ovarian cancer	3.81e-05	0.00168	CbGpPWpGaD
Methyldopa—COMT—Metabolism—FASN—ovarian cancer	3.79e-05	0.00168	CbGpPWpGaD
Methyldopa—COMT—Metabolism—SLC5A5—ovarian cancer	3.73e-05	0.00165	CbGpPWpGaD
Methyldopa—COMT—Metabolism—SLC2A1—ovarian cancer	3.6e-05	0.0016	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—HRAS—ovarian cancer	3.52e-05	0.00156	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CYP1B1—ovarian cancer	3.46e-05	0.00153	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PPP2R1A—ovarian cancer	3.45e-05	0.00153	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CD—ovarian cancer	3.43e-05	0.00152	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ABCB1—ovarian cancer	3.21e-05	0.00142	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYTB—ovarian cancer	3.16e-05	0.0014	CbGpPWpGaD
Methyldopa—DDC—Metabolism—TYMS—ovarian cancer	3.15e-05	0.00139	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BCL9—ovarian cancer	3.1e-05	0.00137	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PPP2R1A—ovarian cancer	3.06e-05	0.00136	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SOD1—ovarian cancer	3.02e-05	0.00134	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PPP2R1A—ovarian cancer	3e-05	0.00133	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CB—ovarian cancer	2.99e-05	0.00132	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ABCB1—ovarian cancer	2.85e-05	0.00126	CbGpPWpGaD
Methyldopa—COMT—Metabolism—TYMS—ovarian cancer	2.8e-05	0.00124	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPP1CC—ovarian cancer	2.76e-05	0.00122	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—BRIP1—ovarian cancer	2.76e-05	0.00122	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—IL2—ovarian cancer	2.75e-05	0.00121	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CXCL8—ovarian cancer	2.73e-05	0.00121	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CAV1—ovarian cancer	2.54e-05	0.00112	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DOK1—ovarian cancer	2.45e-05	0.00109	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—ovarian cancer	2.33e-05	0.00103	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CG—ovarian cancer	2.31e-05	0.00102	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PPP1CC—ovarian cancer	2.31e-05	0.00102	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CAV1—ovarian cancer	2.25e-05	0.000997	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—CAV1—ovarian cancer	2.21e-05	0.000977	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	2.21e-05	0.000977	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	2.17e-05	0.000962	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	2.1e-05	0.000929	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CG—ovarian cancer	2.05e-05	0.000908	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CD—ovarian cancer	2.03e-05	0.000899	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CG—ovarian cancer	2.01e-05	0.00089	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—YAP1—ovarian cancer	1.85e-05	0.000819	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	1.82e-05	0.000806	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CD—ovarian cancer	1.8e-05	0.000798	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CB—ovarian cancer	1.77e-05	0.000784	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CD—ovarian cancer	1.77e-05	0.000782	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HDAC6—ovarian cancer	1.75e-05	0.000774	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PPP2R1A—ovarian cancer	1.72e-05	0.000763	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CXCL8—ovarian cancer	1.66e-05	0.000733	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CB—ovarian cancer	1.57e-05	0.000696	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—YAP1—ovarian cancer	1.55e-05	0.000685	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CB—ovarian cancer	1.54e-05	0.000682	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTEN—ovarian cancer	1.53e-05	0.000677	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—XIAP—ovarian cancer	1.52e-05	0.000671	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—FASN—ovarian cancer	1.51e-05	0.000667	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	1.49e-05	0.000659	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC5A5—ovarian cancer	1.48e-05	0.000656	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SMARCA4—ovarian cancer	1.48e-05	0.000654	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EREG—ovarian cancer	1.44e-05	0.000638	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC2A1—ovarian cancer	1.43e-05	0.000634	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IL2—ovarian cancer	1.42e-05	0.000626	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP1B1—ovarian cancer	1.37e-05	0.000608	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTEN—ovarian cancer	1.36e-05	0.000601	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PGR—ovarian cancer	1.35e-05	0.000598	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CG—ovarian cancer	1.27e-05	0.000562	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PARP1—ovarian cancer	1.26e-05	0.000556	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPP2R1A—ovarian cancer	1.22e-05	0.000539	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—VEGFA—ovarian cancer	1.2e-05	0.000532	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6ST—ovarian cancer	1.2e-05	0.000532	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NRAS—ovarian cancer	1.19e-05	0.000526	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CG—ovarian cancer	1.15e-05	0.000511	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MAPK3—ovarian cancer	1.14e-05	0.000503	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCB1—ovarian cancer	1.13e-05	0.000501	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CD—ovarian cancer	1.12e-05	0.000494	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—TYMS—ovarian cancer	1.11e-05	0.000492	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MAPK1—ovarian cancer	1.08e-05	0.000479	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CA—ovarian cancer	1.08e-05	0.000478	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—KRAS—ovarian cancer	1.02e-05	0.000452	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PPP2R1A—ovarian cancer	1.02e-05	0.000451	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CD—ovarian cancer	1.01e-05	0.000449	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CB—ovarian cancer	9.74e-06	0.000431	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CA—ovarian cancer	9.58e-06	0.000424	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CA—ovarian cancer	9.39e-06	0.000416	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCL8—ovarian cancer	9.36e-06	0.000414	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TP53—ovarian cancer	9.09e-06	0.000402	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CAV1—ovarian cancer	8.95e-06	0.000396	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—IL2—ovarian cancer	8.94e-06	0.000396	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CB—ovarian cancer	8.84e-06	0.000391	CbGpPWpGaD
Methyldopa—DDC—Metabolism—AKT1—ovarian cancer	8.82e-06	0.00039	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—HRAS—ovarian cancer	8.69e-06	0.000385	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCL8—ovarian cancer	8.5e-06	0.000376	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CG—ovarian cancer	8.15e-06	0.000361	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL2—ovarian cancer	8.12e-06	0.000359	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TERT—ovarian cancer	8.09e-06	0.000358	CbGpPWpGaD
Methyldopa—COMT—Metabolism—AKT1—ovarian cancer	7.83e-06	0.000346	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—AKT1—ovarian cancer	7.67e-06	0.00034	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CAV1—ovarian cancer	7.48e-06	0.000331	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ESR1—ovarian cancer	7.21e-06	0.000319	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CD—ovarian cancer	7.17e-06	0.000317	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6ST—ovarian cancer	7.1e-06	0.000314	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APC—ovarian cancer	6.82e-06	0.000302	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CG—ovarian cancer	6.82e-06	0.000302	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—NRAS—ovarian cancer	6.82e-06	0.000302	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MAPK3—ovarian cancer	6.53e-06	0.000289	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CB—ovarian cancer	6.25e-06	0.000276	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MAPK1—ovarian cancer	6.21e-06	0.000275	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EGFR—ovarian cancer	6.21e-06	0.000275	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CD—ovarian cancer	5.99e-06	0.000265	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CA—ovarian cancer	5.94e-06	0.000263	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—KRAS—ovarian cancer	5.87e-06	0.00026	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTEN—ovarian cancer	5.4e-06	0.000239	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	5.39e-06	0.000239	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	5.29e-06	0.000234	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	5.22e-06	0.000231	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	5.22e-06	0.000231	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	5.02e-06	0.000222	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	4.99e-06	0.000221	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	4.9e-06	0.000217	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	4.85e-06	0.000215	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	4.8e-06	0.000213	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL2—ovarian cancer	4.8e-06	0.000212	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	4.77e-06	0.000211	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	4.68e-06	0.000207	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	4.63e-06	0.000205	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	4.54e-06	0.000201	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	4.51e-06	0.0002	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	4.4e-06	0.000195	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	4.08e-06	0.00018	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	4.04e-06	0.000179	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	4.03e-06	0.000178	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	3.86e-06	0.000171	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CA—ovarian cancer	3.81e-06	0.000169	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MYC—ovarian cancer	3.75e-06	0.000166	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	3.67e-06	0.000162	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	3.67e-06	0.000162	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	3.47e-06	0.000153	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	3.18e-06	0.000141	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AKT1—ovarian cancer	3.11e-06	0.000138	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TP53—ovarian cancer	3.08e-06	0.000136	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	2.95e-06	0.00013	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6—ovarian cancer	2.82e-06	0.000125	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	2.6e-06	0.000115	CbGpPWpGaD
